The Institute for Clinical and Economic Review may soon join a key Medicaid commission in recommending the US consider a new way of pricing and reimbursing drugs granted accelerated approval where prices would be set low to account for the unproven clinical benefit, then rise as new confirmatory evidence becomes available.
ICER is coming out with a white paper on the accelerated approval pathway on Monday, 26 April and questions and...